[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,75,104,130,162,183,222],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100634746","safety-and-effectiveness-of-ultrasound-guided-pharmacopuncture-for-spinal-diseases-100634746",false,"NCT07543692","Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases","Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases: A Multi-center, Registry Study","Inclusion Criteria:\n\n1. Patients diagnosed with spinal diseases (KCD codes M and S).\n2. Patients whose Numeric Rating Scale (NRS) score for the most predominant pain (neck pain with upper limb radiating pain OR low back pain with lower limb radiating pain) caused by spinal diseases is 5 or higher.\n3. Outpatients or inpatients scheduled to utilize an ultrasound scan during pharmacopuncture (the decision to perform ultrasound-guided pharmacopuncture is made according to the clinician's routine medical judgment, not for research purposes).\n4. Patients who voluntarily agree to participate in the clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have difficulty completing the written informed consent form.\n2. Women who are pregnant, planning to become pregnant, or breastfeeding.\n3. Patients deemed inappropriate for study participation by the investigator due to severe underlying diseases (e.g., cancer or other malignant neoplasms) that may interfere with treatment effects or result interpretation.\n4. Individuals who are deemed unsuitable for participation in the clinical study by the researcher.","ALL","19 Years","69 Years",{"count":20,"type":21},600,"ESTIMATED","8 Weeks","OBSERVATIONAL","This multi-center registry study aims to evaluate the safety and effectiveness of ultrasound-guided pharmacopuncture for patients diagnosed with spinal diseases. A total of 600 patients, aged 19 to under 70 years, will be enrolled across six Korean medicine hospitals. Eligible participants must have a pain Numeric Rating Scale (NRS) of 5 or higher for their most dominant spinal pain, which includes neck pain with upper extremity radiating pain, or low back pain with lower extremity radiating pain. As a non-interventional observational study, it will include patients who are already planned to receive ultrasound-guided pharmacopuncture as part of their routine clinical care. The primary outcome is the change in the most dominant spinal pain intensity measured by the NRS from baseline to 4 weeks. Secondary outcomes include functional disability evaluated using the Neck Disability Index (NDI) or Oswestry Disability Index (ODI), quality of life using the EQ-5D-5L, and patient satisfaction. Safety will be closely monitored by assessing all adverse events at every visit, evaluating their incidence, severity, and causality related to the procedure. Participants will be selected based on strict inclusion and exclusion criteria to ensure safety and consistency. Ethical standards including informed consent, data privacy, and ongoing safety monitoring will be rigorously upheld throughout the study.",[26,27,28,29],"Spinal Disease","Neck Pain","Low Back Pain","Radiculopathy",[31,32,33,34,35,36],"Pharmacopuncture","Ultrasound-guided","Registry","Observational Study","Korean Medicine","Spinal Pain","NOT_YET_RECRUITING","2026-04-27",{"date":40,"type":41},"2026-05-01","ACTUAL",{"date":43,"type":21},"2026-04-28",{"date":45,"type":21},"2027-12-31",{"name":47,"class":48},"Jaseng Medical Foundation","OTHER",6,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100493794","phase-2-phase-ii-cohort-of-spinal-stereotactic-radiotherapy-in-patients-using-a-mr-linac-100493794","NCT05709782","Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC","INCLUSION CRITERIA:\n\n1. Age ≥ 18 years old\n2. Radiographically documented disease of the spine within 4 weeks of registration (candidates with or without epidural disease allowed)\n3. Candidate for spine SRS\u002FSBRT as determined by treating Radiation Oncologist or Multidisciplinary Spine Conference review\n4. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated allowed\n5. Diagnosis of cancer documented\n6. Motor strength ≥ 4 out of 5 in the extremity affected by the level of spinal disease planned for radiation\n7. Karnofsky Performance score (KPS) ≥ 40 or ECOG score ≤ 3\n\nEXCLUSION CRITERIA:\n\n1. Patients with highly radiosensitive histologies likely to respond to conventional radiation therapy alone (ie lymphoma, multiple myeloma, etc)\n2. Patients who are unable to undergo MRI of the spine with contrast\n3. Patients who are pregnant","18 Years",{"count":58,"type":21},40,"INTERVENTIONAL",[61],"PHASE2","To learn whether giving spinal stereotactic radiosurgery (SRSS) that uses a more advanced imaging scan method called Magnetic Resonance imaging with a Linear Accelerator (MR-LINAC) during treatment will lead to improved responses to treatment and better quality of life. SRSS is radiation therapy given to the area around your spine.",[26],"RECRUITING","2026-01-13",{"date":67,"type":41},"2026-01-14",{"date":69,"type":41},"2023-05-09",{"date":71,"type":21},"2026-01-31",{"name":73,"class":48},"M.D. Anderson Cancer Center",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":59,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":74},"100576990","phase-4-influence-of-lidocaine-infusion-on-motor-evoked-potential-thresholds-100576990","NCT06792474","Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds","Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds; a Single-center, Double-blinded, Randomized Trial for Patients Undergoing Spin Surgery With Intraoperative Neurophysiologic Monitoring.","Inclusion Criteria:\n\n* Patients undergoing elective cervical or thoracolumbar spine surgery with intraoperative neurophysiological monitoring\n\nExclusion Criteria:\n\n* Inability to provide informed consent in English\n* Pregnancy (based on patient report or a positive test on the day of surgery)\n* Contraindication to lidocaine\n* Planned post-operative intubation\n* Current incarceration",true,{"count":84,"type":21},44,[86],"PHASE4","The purpose of this study is to determine the effect of lidocaine infusion on intraoperative neuromonitoring in patients undergoing spine surgery.",[26,89,90],"Anesthesia","Post Operative Pain",[92,93,94,90],"Lidocaine","Intraoperative Neuromonitoring","Spine surgery","2025-11-19",{"date":97,"type":41},"2025-11-24",{"date":99,"type":21},"2026-08",{"date":101,"type":21},"2027-08",{"name":103,"class":48},"Dartmouth-Hitchcock Medical Center",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100422031","ossimend-ba-in-posterolateral-instrumented-lumbar-fusion-100422031","NCT04775537","OssiMend BA in Posterolateral Instrumented Lumbar Fusion","OssiMend Bioactive Moldable in Posterolateral Instrumented Lumbar Fusion","Inclusion Criteria:\n\n* Subject must be 18 years of age or older at the time of consent and must have a documented diagnosis of degenerative disc disease (DDD) that has failed to respond to nonoperative treatment for at least 6 months. DDD is defined by back and\u002For radicular pain with degeneration of the disc as confirmed by medical history, physical examination, and radiographic studies that may include CT, MRI, plain X-ray film, discography, myelography, etc. with one or more of the following findings:\n\n  * Instability as defined by \\>3mm translation or \\>5 degrees angulation\n  * Osteophyte formation of facet joints or vertebral endplates\n  * Decreased disc height, on average by \\>2mm, but dependent upon the spinal level\n  * Herniated nucleus pulposus\n  * Facet joint degeneration\u002Fchanges\n\nExclusion Criteria:\n\n1. Subject is under 18 years of age at the time of consent\n2. Subject has had prior lumbar spine fusion surgery at any level\n3. Subject is currently undergoing treatment for malignancy or has undergone treatment for malignancy\n4. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis\n5. Subject has an active (local or systemic) infection or is undergoing adjunctive treatment for infection\n6. Subjects under workers compensation or active litigation",{"count":112,"type":21},120,"The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material",[26,115],"Degenerative Disc Disease",[117,118],"Bone Graft","Lumbar Fusion","2025-10-14",{"date":121,"type":41},"2025-10-16",{"date":123,"type":41},"2021-01-21",{"date":125,"type":21},"2027-01-30",{"name":127,"class":128},"Collagen Matrix","INDUSTRY",4,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":59,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100585011","a-pilot-study-on-app-based-treatment-combining-physical-exercise-graded-activity-and-pain-journaling-for-patients-with-spinal-complaints-100585011","NCT06896812","A Pilot Study on App-based Treatment Combining Physical Exercise, Graded Activity, and Pain Journaling for Patients with Spinal Complaints","SPINAPP","Inclusion Criteria:\n\n* Patients visiting the spine-centre at Zuyderland Medical Centre.\n* Suffering from spinal complaints for which in current practice physical therapy, general lifestyle advice, or an expectant treatment would be advised.\n* Minimum age of 18 years.\n* Psychosocially, mentally, and physically able to fully comply with this study protocol.\n* Informed consent prior to this study.\n\nExclusion Criteria:\n\n* Requiring a specific intervention (e.g., surgery, pain treatment, rehabilitation, bracing)\n* Inadequate command of the Dutch language.\n* Digitally illiterate or otherwise unable to use an application on a mobile phone.\n* Active spinal infection.\n* Immature bone (ongoing growth).\n* Active malignancy.\n* Pregnancy.",{"count":138,"type":21},30,[140],"NA","Background: The prevalence of spinal complaints such as low back pain is rising due to factors like aging, sedentary lifestyle, and obesity. Traditional conservative treatments include physical therapy and lifestyle modifications. The digital revolution in healthcare has introduced app-based interventions as a promising alternative.\n\nRationale: Given the high burden of spinal complaints and the associated economic impact, there is need for effective and efficient treatment modalities. This is especially evident in Western healthcare systems with growing demands and limited resources due to the changing demographic of the population. An app-based approach offers a viable solution by combining evidence-based conservative treatments. Moreover, an app-based treatment could offer personalized treatment, real-time feedback, and enhanced patient engagement at lower costs, presents as a viable solution.\n\nObjective: This pilot study aims to evaluate the efficacy of an app-based treatment method combining physical exercise, graded activity, and pain journaling for patients with spinal complaints who will otherwise receive physical therapy, general lifestyle advice, or an expectant treatment in current practice.\n\nStudy design: Single center prospective study.\n\nStudy population: A total of 30 patients over 18 years old suffering from spinal complaints for which in current practice physical therapy, general lifestyle advice, or an expectant treatment will be advised.\n\nIntervention: An app-based treatment consisting of a combination of physical exercise, graded activity, and pain journaling.\n\nMain study parameters\u002Fendpoints: Primary endpoint: Patients' experience and satisfaction qualitatively, measured using semi-structured face-to-face interviews after three months of treatment.\n\nSecondary endpoints: Quality of Life (Qol) measured with the EuroQol 5 dimensions (EQ-5D-5L) at baseline, one, two and three months after starting the intervention. Change in back- and leg-pain, measured with the Visual Analogue Scale (VAS). Change in disability, measured with the Oswestry Disability Index (ODI). Change in catastrophizing of pain, measured with the Pain Catastrophizing Scale (PCS). Change in lost productivity, measured with patient reported missed working days. Healthcare consumption, measured with number of visits to doctor or paramedic. Change in Body Mass Index, measured using patients' input on length and weight. Adherence of participants measured using frequency of patients' input in the mobile application. Safety measured using the (serious) adverse events ((S)AE).\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: The nature and extent of the burden associated with participation in the app-based treatment program primarily involve adherence to recommended activities and inputting relevant health data. Given that the investigators are integrating existing treatment modalities, such as physical exercise, graded activity, and pain journaling, the risks associated with participation are minimal, as these interventions are already deemed safe and widely practiced. The responsibility for determining each patient's suitability for participation in this study lies with the referring physician. Participants can expect benefits such as improved pain management, enhanced physical function, and better overall well-being.",[143,26,144],"Back Pain","Spinal Condition",[146,147,148,149,150,151,152],"conservative","app","spine","ehealth","e-health","back pain","graded activity","2025-03-24",{"date":155,"type":41},"2025-03-26",{"date":157,"type":21},"2025-04-01",{"date":159,"type":21},"2025-09-01",{"name":161,"class":48},"Zuyderland Medisch Centrum",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":82,"sex":16,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":74},"100541840","gait-analysis-and-degenerative-spine-100541840","NCT06335095","Gait Analysis and Degenerative Spine","Inclusion Criteria:\n\n* Age between 50 and 85 years\n* Diagnosis of spinal disease by clinical and imagiological criteria\n* More than 3 months duration of disease\n* Ability to give consent\n* Fluent portuguese speaker\n\nExclusion Criteria:\n\n* Previous spine surgery\n* Spinal instability\n* Neurological disease that might interfere with walking\n* Known orthopedic conditions that causes significant gait impairment\n* Dementia or development disorder with cognitive impairment\n* Inability to give consent","50 Years","85 Years",{"count":171,"type":21},200,"The goal of this observational study is to analyse the biomechanics of a degenerative spinal disease. The main questions it aims to answer are:\n\n* What are the biomechanical variables affected by the disease\n* How they evolve with disease progression and treatment",[26],"2025-03-13",{"date":176,"type":41},"2025-03-19",{"date":178,"type":41},"2024-04-01",{"date":180,"type":21},"2026-09",{"name":182,"class":48},"Universidade Nova de Lisboa",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":193,"conditions":194,"keywords":208,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":74},"100486132","gene-expression-profiles-in-spinal-tuberculosis-100486132","NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","Comparing Gene Expression Profiles of Adults With Isolated Spinal TB to Disseminated Spinal TB Identified by 18FDG-PET\u002FCT at Time of Diagnosis, 6-and 12-months Follow-up","SpinalTBX","Inclusion Criteria\n\n1. Participant has completed the written informed consent process prior to undergoing any clinical evaluations and willing to undergo HIV testing\n2. TB spine based on clinical and radiological criteria\n3. Age 18 or older with a body weight of at least 40 kg body weight\n4. Able and willing to return to follow-up\n5. Willing to have samples, including DNA including RNA extraction, stored\n6. Willing to consistently practice a highly reliable method of pregnancy prevention\n\nExclusion Criteria\n\n1. Pregnancy or active desire to become pregnant within the next 6 months.\n2. Uncontrolled diabetes (HbA1c ≥ 6.5% \u002F random glucose concentration ≥11.1 mmol\u002Fl, fasting plasma glucose ≥ 7.0 mmol\u002Fl)\n3. Alcohol and substance abuse which might interfere with medication adherence during the trial\n4. Positive SARS-CoV-2 PCR in the past 4 weeks\n5. Suspicion of malignancy on MRI or known malignancy\n6. Suspicion of inflammatory disease and other rheumatological conditions\n7. Any person for whom the physician feels this study is not appropriate",{"count":192,"type":21},100,"Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB. South Africa has one of the highest HIV and TB rates worldwide with an HIV prevalence rate in adults of 19% and a TB case notification rate of 615\u002F100,000 in 2019. Over many years, focus has been paid to pulmonary TB and extrapulmonary TB (EPTB) has received only little attention even though it accounts for almost a quatre of all TB cases. The diagnosis of EPTB remains challenging simply because sample collection requires invasive procedures in the absence of a blood-based diagnostic test. Spinal TB (spondylitis or spondylodiscitis caused by Mycobacterium tuberculosis) - often known as Pott's disease - accounts for up to 10% of EPTB and affects young children, people with HIV-coinfection and elderly, and often leads to lifelong debilitating disease due to devastating deformation of the spine and compression of neural structures. Little is known with regards to the extent of disease and isolated TB spine as well as a disseminated form of TB spine have been described. The latter presents with a spinal manifestation plus disseminations to other organs such as the lungs, pleura, lymph nodes, the GIT or urinary tract or even the brain.\n\nIn the Spinal TB X cohort, the investigators aim to describe the clinical phenotype of spinal TB using whole body PET\u002FCT and identify a specific gene expression profile for the different stages of dissemination and compare findings to previously described signatures for latent and active pulmonary TB. A blood-based test for spinal TB would lead to earlier diagnosis and treatment in all settings globally and improve treatment outcome of this devastating disease.",[195,196,197,198,199,200,201,26,202,203,204,205,206,207],"Tuberculosis, Spinal","Tuberculosis, Osteoarticular","Tuberculosis","Mycobacterium Infections","Infections","Bone Diseases, Infectious","Musculoskeletal Diseases","Spondylitis","Spondylitis; Tuberculosis (Manifestation)","Spondylodiscitis","Positron-Emission Tomography","Diagnostic Imaging","Diagnostic Techniques and Procedures",[209,210,211,212],"Spinal TB","tuberculous spondylodiscitis","FDG-PET\u002FCT","POC","2024-08-22",{"date":215,"type":41},"2024-08-23",{"date":217,"type":41},"2022-10-25",{"date":219,"type":21},"2026-12-31",{"name":221,"class":48},"University of Cape Town",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":59,"phases":233,"briefSummary":234,"conditions":235,"keywords":242,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":74},"100550785","phase-2-fecal-microbiota-transplantation-in-axial-spondyloarthritis-100550785","NCT06451588","Fecal Microbiota Transplantation in Axial Spondyloarthritis","Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial","MicroSpA","Inclusion Criteria:\n\n* Axial Spondyloarthritis according to the ASAS classification criteria\n* Active disease defined as ASDAS ≥2.1 with elevated CRP ≥4 OR active inflammation on MRI within the last 3 months\n* Onset of axial SpA within last 10 years\n* Unsatisfactory relief of NSAIDs\n* On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months\n\nExclusion Criteria:\n\n* Planned dose adjustment or change in immunomodulatory treatment the next 90 days\n* Disease or disorder with life expectancy of ≤5 years\n* Severe immune deficiency (acquired, congenital og du to medication)\n* Previous treatment with FMT\n* Regular use of opioids with the exception of codeine and tramadol\n* Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease)\n* Inflammatory spinal disease other than axSpA\n* Severe psychiatric disorder, alcohol- or drug abuse\n* Active inflammatory bowel disease\n* Microscopic colitis, diverticulitis or ileus\n* Active psoriasis\n* Fibromyalgia\n* Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery\n* Malignant disease excluding basalioma and melanoma stage 1\n* Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers\n* Treatment with antibiotics 12 weeks prior to study entry\n* Pregnancy, lactation or planned pregnancy within the next 3 months\n* Contraindications for rectal catheter insertion\n* Planned rehabilitation program the next 90 days\n* Limited ability to comply with protocol requirements, including biobank participation","65 Years",{"count":232,"type":21},99,[61],"Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints.\n\nIt has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy.\n\nThe goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy.\n\nThe main questions it aims to answer are:\n\n* Can FMT reduce disease activity in axial SpA?\n* Can FMT alleviate pain and reduce fatigue in axial SpA?\n* Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT?\n\nParticipants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.",[236,237,238,239,202,240,201,26,241],"Axial Spondyloarthritis","Ankylosing Spondylitis","Dysbiosis","Spondyloarthritis","Arthritis","Joint Diseases",[236,243,244,245,246,247],"Microbiome","Fecal Microbiota Transplantation","Microbiota","FMT","RCT","2024-06-04",{"date":250,"type":41},"2024-06-11",{"date":252,"type":41},"2024-06-01",{"date":254,"type":21},"2026-03",{"name":256,"class":48},"University Hospital of North Norway"]